Concord Biotech Limited (NSE:CONCORDBIO)

Concord Biotech Statistics

Total Valuation

Concord Biotech has a market cap or net worth of INR 167.81 billion. The enterprise value is 164.67 billion.

Market Cap	167.81B
Enterprise Value	164.67B

Important Dates

The next estimated earnings date is Wednesday, August 13, 2025.

Earnings Date	Aug 13, 2025
Ex-Dividend Date	Sep 3, 2025

Share Statistics

Concord Biotech has 104.62 million shares outstanding. The number of shares has increased by 0.05% in one year.

Current Share Class	104.62M
Shares Outstanding	104.62M
Shares Change (YoY)	+0.05%
Shares Change (QoQ)	+0.04%
Owned by Insiders (%)	61.27%
Owned by Institutions (%)	14.71%
Float	26.20M

Valuation Ratios

The trailing PE ratio is 47.14 and the forward PE ratio is 37.87. Concord Biotech's PEG ratio is 1.65.

PE Ratio	47.14
Forward PE	37.87
PS Ratio	14.12
PB Ratio	9.26
P/TBV Ratio	9.26
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	1.65

Enterprise Valuation

EV / Earnings	46.24
EV / Sales	13.86
EV / EBITDA	34.21
EV / EBIT	38.63
EV / FCF	n/a

Financial Position

Current Ratio	n/a
Quick Ratio	n/a
Debt / Equity	0.00
Debt / EBITDA	0.01
Debt / FCF	n/a
Interest Coverage	1,231.57

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	15.94%
Return on Capital Employed (ROCE)	n/a
Revenue Per Employee	8.63M
Profits Per Employee	2.59M
Employee Count	1,377
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Concord Biotech has paid 1.18 billion in taxes.

Income Tax	1.18B
Effective Tax Rate	24.83%

Stock Price Statistics

The stock price has increased by +3.29% in the last 52 weeks. The beta is 0.96, so Concord Biotech's price volatility has been similar to the market average.

Beta (5Y)	0.96
52-Week Price Change	+3.29%
50-Day Moving Average	1,852.21
200-Day Moving Average	1,862.32
Relative Strength Index (RSI)	27.62
Average Volume (20 Days)	150,190

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Concord Biotech had revenue of INR 11.88 billion and earned 3.56 billion in profits. Earnings per share was 34.03.

Revenue	11.88B
Gross Profit	7.71B
Operating Income	4.27B
Pretax Income	4.74B
Net Income	3.56B
EBITDA	4.82B
EBIT	4.27B
Earnings Per Share (EPS)	34.03

Balance Sheet

The company has 3.18 billion in cash and 29.69 million in debt, giving a net cash position of 3.15 billion or 30.09 per share.

Cash & Cash Equivalents	3.18B
Total Debt	29.69M
Net Cash	3.15B
Net Cash Per Share	30.09
Equity (Book Value)	18.13B
Book Value Per Share	173.28
Working Capital	n/a

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 64.92%, with operating and profit margins of 35.97% and 29.97%.

Gross Margin	64.92%
Operating Margin	35.97%
Pretax Margin	39.87%
Profit Margin	29.97%
EBITDA Margin	40.60%
EBIT Margin	35.97%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 10.70, which amounts to a dividend yield of 0.67%.

Dividend Per Share	10.70
Dividend Yield	0.67%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	1
Payout Ratio	n/a
Buyback Yield	-0.05%
Shareholder Yield	0.62%
Earnings Yield	2.12%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1